MARA Announces Fourth Quarter and Fiscal Year 2025 Results Miami, FL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ) ("MARA" or the "Company"), a leading energy and digital infrastructure company, today announced its preliminary, unaudited fourth quarter and fiscal year 2025 financial results in a letter to shareholders. Investors are invited to access the fourth quarter 2025 shareholder letter at MARA’s website at ir.mara.com. A copy of the letter will also be furnished to the Securities and Exchange Commission on a Form 8-K. MARA will hold a webcast and conference call at 5:00 p.m. Eas...
MARA Announces Strategic Partnership with Starwood to Accelerate Delivery of Cutting Edge Hyperscale, Enterprise and AI Capable Digital Infrastructure Joint Platform Expected to Deliver Approximately 1 GW of Near-Term IT Capacity, with Pathway to More than 2.5 GW Miami, FL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA), a leading energy and compute infrastructure company, today announced it has entered into a strategic agreement with Starwood Capital Group (“Starwood”) and their dedicated data center development platform Starwood Digital Ventures (“SDV”). The par...
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Bo...
MARA Schedules Conference Call for Fourth Quarter and Fiscal Year 2025 Financial Results Earnings Webcast and Conference Call Set for Thursday, February 26, 2026 at 5:00 p.m. ET Miami, FL, Feb. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ) ("MARA" or the "Company"), a leading digital energy and infrastructure company, will hold a webcast and conference call on Thursday, February 26, 2026 at 5:00 p.m. Eastern time to discuss its financial results for the quarter and fiscal year ended December 31, 2025. Financial results will be published in a shareholder letter prior to the call on the investo...
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 Noninferiority Trial, Continues to Enroll Subjects, with Topline Data Expected in Fourth Quarter of 2026 Vaxcyte’s VAX-31 Phase 3 Adult Clinical Program – Finalized in Consultation and Alignment with U.S. Food and Drug Administrati...
Aqua Metals Enters Into a Term Sheet to Acquire Leading Energy Storage Company Lion Energy Combined Entity Would Integrate Energy Storage Products, Proprietary Energy Management Software, Recycling, and Battery Materials into a Single Platform Lion Energy is a Revenue-Generating Business, Enhanced by Proprietary Software and Positioned to Participate in Expanding Energy & Virtual Power Plant Markets RENO, Nev. and AMERICAN FORK, Utah, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in battery metals recycling and refining, today announced that it has entere...
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT. To participate in the conference call, please dial 800-445-7795 (domestic) or ...
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at . A replay of the webcast will be available for approximately 30 days foll...
Aqua Metals and American Battery Factory Announce Proposed Strategic Collaboration to Advance Domestic Circular Supply of Battery Materials Strategic collaboration would highlight a cost-competitive, domestic alternative to overseas battery materials processing TUCSON, Ariz. and RENO, Nev. , Feb. 03, 2026 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in clean metals recycling and refining, and American Battery Factory (ABF), a lithium iron phosphate (LFP) battery cell manufacturer, today announced a proposed strategic collaboration focused on advancing a more competiti...
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer Brings more than 25 years of biopharma business development and corporate strategy expertise BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio’s business development strategy and execution, with responsibility for licensing, partn...
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,650,000 additional shares of common stock at the public offering pr...
Aqua Metals to Participate in NAATBatt 2026 Annual Meeting in Tucson; Discuss Commercial and Technical Milestones in Domestic Battery Materials RENO, Nev., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable battery metals recycling and refining, today announced that members of its executive and technical teams will participate in the NAATBatt 2026 Annual Meeting, taking place February 9–12, 2026, in Tucson, Arizona. The NAATBatt Annual Meeting brings together leaders from across the battery and energy storage ecosystem, including manufacturers, m...
Vaxcyte Announces Pricing of $550 Million Public Offering SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock to be s...
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of shares of its common stoc...
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults Previously Vaccinated with Pneumococcal Vaccines (OPUS-3) in First Quarter of 2026 Company Expects to Report Topline Safety, Tolerability and Immunogenicity Data from Both OPUS-2 and OPUS-3 Phase 3 Studies in First Half of 2027, Supporting Planned BLA Subm...
Aqua Metals and 6K Energy Execute Multi-Year Supply Agreement to Support Domestic Battery Materials Commercialization Multi-Year Supply Agreement with 6K Energy Marks Commercial Milestone for AquaRefining™ Technology and Domestic Battery Materials Strategy RENO, Nev., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable battery metals recycling and refining, today announced the execution of a multi-year Material Supply Agreement (MSA) with 6K Energy, a leading U.S.-based producer of advanced cathode active materials (CAM). The agreement establishe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.